Prevention of Cardiovascular Outcomes in Diabetic Patients With Atrial Fibrillation: Direct Oral Anticoagulants or Warfarin?

Clinical pharmacology and therapy
doi 10.32756/0869-5490-2019-3-5-13
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Pharmapress LLC

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy